LC-MS/MS extends the range of drug analysis in pain patients

Therapeutic Drug Monitoring

Volumn 31, Issue 6, 2009, Pages 746-748

  Mikel, Charles ^a   Almazan, Perla ^a   West, Robert ^a   Crews, Bridgit ^a   Latyshev, Sergey ^a   Pesce, Amadeo ^a   West, Cameron ^a  

^a Millennium Laboratories   (United States)

Author keywords

Excreted drug concentrations; LC MS MS; Low cutoff; Pain patients

Indexed keywords

ALPHA HYDROXYALPRAZOLAM; ALPRAZOLAM; AMPHETAMINE; AMPHETAMINE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABINOID DERIVATIVE; CARISOPRODOL; COCAINE DERIVATIVE; CODEINE; DEXTROPROPOXYPHENE; DRUG METABOLITE; HYDROCODONE; HYDROMORPHONE; LORAZEPAM; MEPROBAMATE; METHADONE; METHAMPHETAMINE; MORPHINE; NORDAZEPAM; NORPROPOXYPHENE; OPIATE DERIVATIVE; OXAZEPAM; OXYCODONE; OXYMORPHONE; TRAMADOL; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; DRUG DETERMINATION; DRUG METABOLISM; DRUG URINE LEVEL; FALSE NEGATIVE RESULT; HUMAN; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; PAIN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANALGESICS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LIMIT OF DETECTION; MEDICATION ADHERENCE; PAIN; REFERENCE VALUES; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY; UNITED STATES; UNITED STATES SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION;

EID: 73849147583     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181c11fba     Document Type: Article

References (11)

1. Armbruster DA. A guide to NIDA certification for workplace drug testing. National Institute on Drug Abuse. Medical Laboratory Observer. February 1992. Available at: http://findarticles.com/p/articles/mi-m3230/is-n2-v24/ai-12073283/ . Accessed May 27, 2009.
2. Mandatory guidelines and proposed revisions to mandatory guidelines for federal workplace drug testing programs; Notices Section 2.4 Laboratory Analysis Procedures (f) (1) confirmatory drug test. Federal Register. 2004;69:19673-19732.
3. US Department of Justice National Drug Intelligence Center. National prescription drug threat assessment. Available at: http://www.usdoj.gov/ ndic/. Accessed May 27, 2009.
4. Manchikanti, L, Manchukonda, R, Pampati, et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006;9;123-129.
5. Cone EJ, Caplan YH, Black DL, et al. Urine drug testing of chronic pain patients: licit and illicit drug patterns. J Anal Toxicol. 2008;32:530-543.
6. State of New York Department of Health. Analytical Toxicology Proficiency Testing Program, 08/2009. Albany, NY: State of New York Department of Health.
7. White RM, Black ML. Pain Management Testing Reference. Washington, DC: AACC Press; 2008: 204-208.
8. Manchikanti L, Cash KA, Damron KS, et al. Controlled substance abuse in illicit drug use in chronic pain patients: an evaluation of multiple variables. Pain Physician. 2006;9:215-226.
9. Mohsin S, Yang Y. Quantitative Analysis of Opiates Using LC/MS/MS. Application. 2007; Santa Clara, CA: Agilent Technologies.
10. Microgenics Corporation. DRI Applications and CEDIA-Olympus AU640. Revision 5. 2007; Fremont, CA: Microgenics Corporation.
11. Trestcott AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician. 2006;9:1-39.